A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...

NEW YORK, NY / ACCESS Newswire / March 1, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want ...

As you can see from the chart above the percentage of shares that are sold short for Regeneron Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall ...

Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...

Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 12.37% on an annualized basis producing an average annual return of 24.38%. Currently, Regeneron ...

SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing ...

If you’re on the fence about investing in Regeneron Pharmaceuticals, Inc., Alnylam Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors ...

Analyst Price Forecast Suggests 42.56% Upside As of January 28, 2025, the average one-year price target for Regeneron Pharmaceuticals is $1,022.63/share. The forecasts range from a low of $570.65 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call.

2025 Effective Tax Rate Guidance: 11% to 13%. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported a strong fourth quarter with 10% revenue growth, driven by key franchises like Dupixent ...